Michela Staderini Selected Research

Melphalan (Alkeran)

1/2021

Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michela Staderini Research Topics

Disease

8	Multiple Myeloma 01/2023 - 01/2015
1	Residual Neoplasm 01/2023
1	Chromosome Aberrations (Chromosome Abnormalities) 02/2021
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2020

Drug/Important Bio-Agent (IBA)

3	Lenalidomide (CC 5013)FDA Link 01/2023 - 01/2015
3	Dexamethasone (Maxidex)FDA LinkGeneric 01/2023 - 01/2015
2	carfilzomibIBA 01/2023 - 02/2021
2	Bortezomib (Velcade)FDA Link 02/2021 - 01/2021
1	Proteasome InhibitorsIBA 01/2023
1	daratumumabIBA 11/2021
1	Prednisone (Sone)FDA LinkGeneric 01/2021
1	Melphalan (Alkeran)FDA LinkGeneric 01/2021
1	Immunoglobulin G (IgG)IBA 01/2020
1	Immunoglobulins (Immunoglobulin)IBA 06/2016
1	Immunomodulating AgentsIBA 01/2015

Therapy/Procedure

2	Therapeutics 02/2021 - 01/2021
2	Stem Cell Transplantation 01/2021 - 02/2020
1	Autologous Transplantation 01/2023
1	Drug Therapy (Chemotherapy) 01/2021